Newsletters
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
The threat of mirror bacteria: Ongoing conversations
Dear All, I wrote in a 12 Dec 2024 newsletter (“Mirror Bacteria: An AMR threat of unprecedented magnitude”) about the ...
Read More >
Updated FDA Q&A on Antibacterials for Unmet Medical Need
Dear All, An updated version of FDA’s very helpful Q&A entitled “Antibacterial Therapies for Patients With an Unmet Medical Need ...
Read More >
UNGA 2024 action: Establishing an Independent Panel on Evidence for Action (IPEA)
Dear All, Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting ...
Read More >
Pull incentives in Europe: Next legislative steps
Dear All (Deeply wonkish alert! Settle in! Great stuff here!): For today, we have a deep dive into the ongoing ...
Read More >
Extending STEDI to diagnostics: STRIDES
Dear All (and with thanks to Betsy Trainor for co-authoring), The idea of the STEDI values of an antibiotic (its ...
Read More >
MHRA compilation of regulatory guidance on phage products
Dear All, Attention phage developers — the UK MHRA have compiled all their regulatory guidance for phage into one convenient ...
Read More >
D-Day: Churchill (1944) → WHO Pandemic Agreement and the Hamburg Statement (2025)
Dear All, D-Day and the momentous Normandy landings were 81 years ago today. In a marvelous new article on bbc.com (and ...
Read More >
FDA Listening Sessions for CEOs, CMOs, or heads of R&D
Dear All, Pushing this one out as a direct quote from the online materials posted yesterday by FDA. Looks interesting! All ...
Read More >
IDWeek 2025: Present your novel antimicrobial or diagnostic
Dear All, As in previous years (27 Mar 2024 newsletter), IDWeek 2025 will feature pipeline-focused sessions for both antimicrobials and ...
Read More >
Vaccine development: Polytheism vs. Monotheism
Dear All (and with a wonkish alert!), The idea of more (and better) vaccines to prevent (or even be part ...
Read More >
Impact of AMR on cancer therapy
Dear All (unapologetically wonkish … very important material!), Let’s set the scene today by considering two quotes: Prosaic: “The successful ...
Read More >
Evolving the idea of DTR (Difficult-to-Treat Resistance) to include antibiotic access
Dear All (wonkish alert … lots of details here … take your time and absorb it all!), I’ve written several ...
Read More >
Vivli’s 2025 AMR Surveillance Data Challenge
Dear All, We’ve previously discussed the availability of large surveillance datasets from the Vivli AMR Register. In particular, you should review Patricia ...
Read More >
Manufacturing underpins access in LMICs: An update on cefiderocol
Dear All, No one is safe until we’re all safe! In the 7 April 2025 newsletter on antibiotic access (“UNSLAP: You ...
Read More >
Most current global summary of Pull incentives
Dear All, I was recently asked about a ready summary of the current state of play of Pull incentives around ...
Read More >
Sign-on letter encouraging AMR funding in the FY2026 US budget
Dear All, If you represent a US-based organization with an interest in AMR, there is an opportunity to sign a ...
Read More >
UNSLAP: You reach for the antibiotic … and it’s not there!
Dear All (with thanks to Louise for co-authoring and with a wonkish alert … settle in for the ride!), Today’s ...
Read More >
Antibacterial R&D is very hard! Two great pipeline reviews + an Industry-level view
Dear All (and with thanks to Stephan Harbarth for co-authoring this newsletter), A new review by Ursula Theuretzbacher and colleagues ...
Read More >
WHO pipeline reviews: Antifungal agents and fungal diagnostics
Dear All, As you know, WHO have been steadfastly producing both priority pathogens lists (PPLs) and pipeline reviews. My current ...
Read More >
Now live: HERA’s call for rapid point-of-care susceptibility devices
Dear All, I wrote in the 19 Feb 2025 newsletter about HERA’s 13m EUR call for rapid point-of-care susceptibility devices. The ...
Read More >